Literature DB >> 6777701

Clinical consequences of acquired transfusional iron overload in adults.

A I Schafer, R G Cheron, R Dluhy, B Cooper, R E Gleason, J S Soeldner, H F Bunn.   

Abstract

We assessed the clinical sequelae of transfusional iron overload in 15 nonthalassemic adults (40 to 71 years of age) with anemias requiring transfusions. Iron loading had been present for less than four years in 14 patients. The number of units of blood transfused ranged from 60 to 210 (mean, 120). Liver-biopsy specimens in 10 patients contained seven to 26 times the normal amount of iron and typically showed focal portal fibrosis. Left ventricular cardiac function was impaired in only the most heavily transfused patients or in those with coexisting coronary-artery disease, All patients had glucose intolerance associated with significantly reduced insulin output, compared with controls (P < 0.01). Pituitary reserve of ACTH was limited in 10 of 12 patients, and that of gonadotropin in five of 13. We conclude that widespread subclinical organ dysfunction can result from transfusional iron overload developing in adulthood. The pattern of organ involvement resembles that encountered in idiopathic hemochromatosis.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6777701     DOI: 10.1056/NEJM198102053040603

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  45 in total

Review 1.  Optimizing therapy for iron overload in the myelodysplastic syndromes: recent developments.

Authors:  Heather A Leitch
Journal:  Drugs       Date:  2011-01-22       Impact factor: 9.546

2.  HFE gene mutations, serum ferritin level, transferrin saturation, and their clinical correlates in a Korean population.

Authors:  Sang Hyub Lee; Jin-Wook Kim; So Hyun Shin; Kyoung Phil Kang; Hyun Cheol Choi; Sung Hee Choi; Kyoung Un Park; Hyun Young Kim; Weechang Kang; Sook-Hyang Jeong
Journal:  Dig Dis Sci       Date:  2008-08-06       Impact factor: 3.199

3.  Dietary and prophylactic iron supplements : Helpful or harmful?

Authors:  S Kent; E D Weinberg; P Stuart-Macadam
Journal:  Hum Nat       Date:  1990-03

Review 4.  Liver iron content determination by magnetic resonance imaging.

Authors:  Konstantinos Tziomalos; Vassilios Perifanis
Journal:  World J Gastroenterol       Date:  2010-04-07       Impact factor: 5.742

5.  Radiologic features of a pyrophosphate-like arthropathy associated with long-term dialysis.

Authors:  E M Braunstein; K Menerey; W Martel; R Swartz; I H Fox
Journal:  Skeletal Radiol       Date:  1987       Impact factor: 2.199

6.  Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study.

Authors:  Emilio Paolo Alessandrino; Matteo Giovanni Della Porta; Andrea Bacigalupo; Luca Malcovati; Emanuele Angelucci; Maria Teresa Van Lint; Michele Falda; Francesco Onida; Massimo Bernardi; Stefano Guidi; Barbarella Lucarelli; Alessandro Rambaldi; Raffaella Cerretti; Paola Marenco; Pietro Pioltelli; Cristiana Pascutto; Rosi Oneto; Laura Pirolini; Renato Fanin; Alberto Bosi
Journal:  Haematologica       Date:  2009-11-10       Impact factor: 9.941

Review 7.  [Individualized management and therapy of myelodysplastic syndromes].

Authors:  Reinhard Stauder; Friedrich Wimazal; Thomas Nösslinger; Otto Krieger; Wolfgang R Sperr; Heinz Sill; Michael Pfeilstöcker; Peter Valent
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

Review 8.  Cardiac iron across different transfusion-dependent diseases.

Authors:  John C Wood
Journal:  Blood Rev       Date:  2008-12       Impact factor: 8.250

9.  Iron chelation therapy in myelodysplastic syndromes.

Authors:  Emanuela Messa; Daniela Cilloni; Giuseppe Saglio
Journal:  Adv Hematol       Date:  2010-06-20

10.  Update on the use of deferasirox in the management of iron overload.

Authors:  Ali Taher; Maria Domenica Cappellini
Journal:  Ther Clin Risk Manag       Date:  2009-11-02       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.